3D Cell Culture - Global Strategic Business Report: Capitalize on 13.9% CAGR to US$3.9 Billion by 2030 as Agilent, Corning, GE Healthcare and Bio-Rad Reshape Drug Discovery

What happened: ResearchAndMarkets.com added the "3D Cell Culture - Global Strategic Business Report" to its offering, covering market trends, technologies, segments, regions, and 38 profiled companies including Agilent, Corning, GE Healthcare, and Why it matters: The report attributes expansion to demand for physiologically relevant research models, drug screening innovation, and adoption across cancer research, regenerative medicine, toxicology, and personalized medicine, with technology advances in scaffolds, microfluidics, and bioprinting improving scalability and reproducibility. Market: +3.0% today ($177.15), +28.9% YTD, 0.3x vol — as of 16:32 UTC

ResearchAndMarkets.com added the "3D Cell Culture - Global Strategic Business Report" to its offering, covering market trends, technologies, segments, regions, and 38 profiled companies including Agilent, Corning, GE Healthcare, and

The report attributes expansion to demand for physiologically relevant research models, drug screening innovation, and adoption across cancer research, regenerative medicine, toxicology, and personalized medicine, with technology advances in scaffolds, microfluidics, and bioprinting improving scalability and reproducibility. Market: +3.0% today ($177.15), +28.9% YTD, 0.3x vol — as of 16:32 UTC